JP7558949B2 - 抗ｃｔｌａ－４結合タンパク質およびその使用方法 - Google Patents

抗ｃｔｌａ－４結合タンパク質およびその使用方法 Download PDF

Info

Publication number
JP7558949B2
JP7558949B2 JP2021537082A JP2021537082A JP7558949B2 JP 7558949 B2 JP7558949 B2 JP 7558949B2 JP 2021537082 A JP2021537082 A JP 2021537082A JP 2021537082 A JP2021537082 A JP 2021537082A JP 7558949 B2 JP7558949 B2 JP 7558949B2
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
ctla
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021537082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516071A (ja
JPWO2020140084A5 (enExample
Inventor
デイビッド スコット ジョンソン，
アダム シュルツ アドラー，
レナ アヴィヴァ ミズラヒ，
ユン ワーン リム，
マイケル アセンシオ，
エリカ リン ストーン，
Original Assignee
ギガジェン，インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギガジェン，インコーポレイティッド filed Critical ギガジェン，インコーポレイティッド
Publication of JP2022516071A publication Critical patent/JP2022516071A/ja
Publication of JPWO2020140084A5 publication Critical patent/JPWO2020140084A5/ja
Priority to JP2024014900A priority Critical patent/JP7745669B2/ja
Application granted granted Critical
Publication of JP7558949B2 publication Critical patent/JP7558949B2/ja
Priority to JP2025100129A priority patent/JP2025128343A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021537082A 2018-12-27 2019-12-27 抗ｃｔｌａ－４結合タンパク質およびその使用方法 Active JP7558949B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024014900A JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ｃｔｌａ－４結合タンパク質およびその使用方法
JP2025100129A JP2025128343A (ja) 2018-12-27 2025-06-16 抗ｃｔｌａ－４結合タンパク質およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
US62/785,659 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024014900A Division JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ｃｔｌａ－４結合タンパク質およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022516071A JP2022516071A (ja) 2022-02-24
JPWO2020140084A5 JPWO2020140084A5 (enExample) 2023-01-10
JP7558949B2 true JP7558949B2 (ja) 2024-10-01

Family

ID=71126610

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021537082A Active JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ｃｔｌａ－４結合タンパク質およびその使用方法
JP2024014900A Active JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ｃｔｌａ－４結合タンパク質およびその使用方法
JP2025100129A Pending JP2025128343A (ja) 2018-12-27 2025-06-16 抗ｃｔｌａ－４結合タンパク質およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024014900A Active JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ｃｔｌａ－４結合タンパク質およびその使用方法
JP2025100129A Pending JP2025128343A (ja) 2018-12-27 2025-06-16 抗ｃｔｌａ－４結合タンパク質およびその使用方法

Country Status (12)

Country Link
US (1) US12421311B2 (enExample)
EP (1) EP3902821A4 (enExample)
JP (3) JP7558949B2 (enExample)
KR (1) KR20210121045A (enExample)
CN (2) CN114008071B (enExample)
AU (2) AU2019413366B2 (enExample)
BR (1) BR112021012588A2 (enExample)
CA (1) CA3124961C (enExample)
IL (2) IL316757A (enExample)
MX (1) MX2021007848A (enExample)
SG (1) SG11202106764YA (enExample)
WO (1) WO2020140084A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532136A (ja) * 2020-07-02 2023-07-26 ギガジェン，インコーポレイティッド 抗ｃｔｌａ－４結合タンパク質及びその使用方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250157457A (ko) * 2015-10-23 2025-11-04 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
IL316757A (en) 2018-12-27 2025-01-01 Gigagen Inc Anti-CTLA-4 binding proteins and methods of using them
AU2021411581A1 (en) * 2020-12-31 2023-07-06 Novarock Biotherapeutics, Ltd. Antibodies to tnfr2 and uses thereof
EP4362981A1 (en) * 2021-07-02 2024-05-08 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
KR20240114766A (ko) * 2021-12-10 2024-07-24 머크 샤프 앤드 돔 엘엘씨 인간 메소텔린 결합제
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508573A (ja) 2015-02-13 2018-03-29 ソレント・セラピューティクス・インコーポレイテッド Ｃｔｌａ４に結合する抗体医薬
WO2018209701A1 (en) 2017-05-19 2018-11-22 Wuxi Biologics (Shanghai) Co., Ltd. Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
EP1793858A4 (en) * 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2014089113A1 (en) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
JP6449338B2 (ja) * 2014-06-06 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
SI3303394T1 (sl) * 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
US10618960B2 (en) 2015-12-15 2020-04-14 Oncoimmune, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018157147A1 (en) 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
IL316757A (en) 2018-12-27 2025-01-01 Gigagen Inc Anti-CTLA-4 binding proteins and methods of using them
TWI850316B (zh) 2019-01-21 2024-08-01 法商賽諾菲公司 用於晚期實性瘤癌症之治療性rna及抗pd1抗體
AU2021299338A1 (en) 2020-07-02 2023-02-23 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508573A (ja) 2015-02-13 2018-03-29 ソレント・セラピューティクス・インコーポレイテッド Ｃｔｌａ４に結合する抗体医薬
WO2018209701A1 (en) 2017-05-19 2018-11-22 Wuxi Biologics (Shanghai) Co., Ltd. Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532136A (ja) * 2020-07-02 2023-07-26 ギガジェン，インコーポレイティッド 抗ｃｔｌａ－４結合タンパク質及びその使用方法
JP7783840B2 (ja) 2020-07-02 2025-12-10 ギガジェン，インコーポレイティッド 抗ｃｔｌａ－４結合タンパク質及びその使用方法

Also Published As

Publication number Publication date
US20220064303A1 (en) 2022-03-03
IL284156B2 (en) 2025-04-01
MX2021007848A (es) 2021-10-26
EP3902821A1 (en) 2021-11-03
CN114008071B (zh) 2025-01-21
JP2022516071A (ja) 2022-02-24
JP2025128343A (ja) 2025-09-02
AU2019413366B2 (en) 2025-06-05
WO2020140084A1 (en) 2020-07-02
CA3124961A1 (en) 2020-07-02
JP7745669B2 (ja) 2025-09-29
IL284156A (en) 2021-08-31
SG11202106764YA (en) 2021-07-29
IL316757A (en) 2025-01-01
CN119930820A (zh) 2025-05-06
BR112021012588A2 (pt) 2021-09-08
KR20210121045A (ko) 2021-10-07
AU2019413366A1 (en) 2021-08-12
IL284156B1 (en) 2024-12-01
AU2025223772A1 (en) 2025-09-18
EP3902821A4 (en) 2022-11-30
CN114008071A (zh) 2022-02-01
US12421311B2 (en) 2025-09-23
JP2024042072A (ja) 2024-03-27
CA3124961C (en) 2025-11-25

Similar Documents

Publication Publication Date Title
JP7745669B2 (ja) 抗ｃｔｌａ－４結合タンパク質およびその使用方法
US20220064302A1 (en) Anti-PD-1 Binding Proteins and Methods of Use Thereof
WO2020140094A1 (en) Anti-b7-h3 binding proteins and methods of use thereof
CN116234821B (zh) 抗ctla-4结合蛋白和其使用方法
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
WO2022006555A2 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
US20220056137A1 (en) Anti-PD-L1 Binding Proteins and Methods of Use Thereof
WO2020140070A1 (en) Anti-b7-h4 binding proteins and methods of use thereof
CA3249127A1 (en) Anti-ctla-4 binding proteins and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240918

R150 Certificate of patent or registration of utility model

Ref document number: 7558949

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150